Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01864109
First received: May 23, 2013
Last updated: August 22, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2019
  Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)